SCHEMBL255188

SCHEMBL255188

C1COC2(C1)CCNCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4689253 0.97
Hydrochloric Acid SCHEMBL31554876 0.97
Pyrrolidine SCHEMBL27162253 0.95 ALDH1A1 (0.36)
SCHEMBL7650866 0.95 CXCR4 (0.30)
SCHEMBL2236109 0.92 KCNH2 (0.33)
SCHEMBL16877799 0.90 CXCR4 (0.30)
Hydrochloric Acid SCHEMBL21590849 0.90 KCNH2 (0.32)
SCHEMBL23509080 0.90 CXCR4 (0.33)
SCHEMBL16878542 0.87 MEN1 (0.33)
SCHEMBL16878730 0.87 CXCR4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-11-20 US claimed
EP-4590672-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-07-30 EP claimed
EP-4547671-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2025-05-07 EP claimed
CN-119907797-A Phthalazine derivatives as NOD-like receptor protein 3 inhibitors 默沙东有限责任公司 2025-04-29 CN claimed
US-20240124451-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 MERCK SHARP & DOHME LLC (US) 2024-04-18 US claimed
WO-2024064245-A1 PHTHALAZINE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 MERCK SHARP & DOHME LLC (US) 2024-03-28 WO claimed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 WO claimed
US-20220289753-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-09-15 US claimed
EP-4010335-A1 SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-06-15 EP claimed
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses RAPT THERAPEUTICS, INC. (US) 2021-06-29 US claimed
EP-1341763-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, WITH GLYCIDYL OR ALKYLCARBONYL GROUPS AS FUNCTIONAL INITIATORS FOR CONTROLLED RADICAL POLYMERIZATION Ciba SC Holding AG (CH) 2003-09-10 EP claimed
US-20030149036-A1 Substituted benzothiazole amide derivatives HOFFMAN-LA ROCHE INC. 2003-08-07 US claimed
WO-2003053361-A2 PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO claimed
WO-2003050099-A1 PHENYLALKYNES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-06-19 WO claimed
WO-2003049741-A1 UREAS OF 2-AMINOBENZOTHIAZOLES AS ADENOSINE MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2003-06-19 WO claimed
WO-2003042186-A1 DITHIOCARBAMATE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Medac Gesellschaft für klinische Spezialpräparate mbH (DE) 2003-05-22 WO claimed
EP-1237891-A1 HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-09-11 EP claimed
WO-2002048109-A2 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINES AS RADICAL POLYMERIZATION INITIATORS CIBA SPECIALTY CHEMICLAS HOLDING INC. (CH) 2002-06-20 WO claimed
WO-2002048205-A1 N-ALKOXY-4,4-DIOXY-POLYALKYL-PIPERIDINE COMPOUNDS, THEIR CORRESPONDING N-OXIDES AND CONTROLLED RADICAL POLYMERIZATION THEREWITH CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2002-06-20 WO claimed
WO-2001040231-A1 HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-06-07 WO claimed